Telix Pharmaceuticals supports the Centers for Medicare & Medicaid Services' proposed changes to the hospital outpatient prospective payment system.

The revisions aim to improve payments for diagnostic radiopharmaceuticals, ensuring ongoing patient access in the US after the transitional pass-through payment status expires.

Under the proposed changes, diagnostic radiopharmaceuticals, including Telix's Illuccix, would continue to receive separate payments from CMS for traditional Medicare fee for service patients in hospital outpatient settings.

The cost of these radiopharmaceuticals in the US is currently bundled with nuclear medicine test payments. CMS's proposal seeks to enhance payment accuracy by covering any diagnostic radiopharmaceutical costing more than US$630 ($932.88) daily.

The proposed OPPS rules are open for comments until Sept. 9, with the final rule expected in early November and implementation set for Jan. 1, 2025.